Companies › Protara Therapeutics
2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 3; Metabolic and endocrine, Oncology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TARA-002 | – | Phase 3 | Bladder (Urothelial, Transitional Cell) Cancer; Lymphatic Malformation; Non-muscle Invasive Bladder Cancer | Dec 2026 |
| Choline Chloride for Injection Essential nutrient and choline precursor for phosphatidylcholine synthesis | – | Phase 2 | Choline Deficiency | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05871970 | TARA-002 | Phase 2 | Lymphatic Malformation | Other | Dec 2026 |
| NCT06910943 | Choline Chloride for Injection | Phase 2 | Choline Deficiency | Metabolic and endocrine | Mar 2028 |
| NCT07480356 | TARA-002 | Phase 3 | Bladder (Urothelial, Transitional Cell) Cancer | Oncology | Apr 2028 |
| NCT05951179 | TARA-002 | Phase 2 | Non-muscle Invasive Bladder Cancer | Oncology | Oct 2031 |
Cash and short-term investments of $127m on 2026-09-30; operating cash outflow about $74m a year; runway about 21 months at that burn, to Jun 2028; 3 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Energenesis Biomedical Relay Therapeutics HTA J-Pharma Kailera
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.